Efficacy News and Research

RSS
New multi-center follow-up study of NX-1207 for treatment of BPH to be completed

New multi-center follow-up study of NX-1207 for treatment of BPH to be completed

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

WPI, Cerus announce positive results from study of INTERCEPT Blood System to inactivate XMRV

WPI, Cerus announce positive results from study of INTERCEPT Blood System to inactivate XMRV

Catalyst Pharmaceutical Partners first-quarter net loss decreases to $0.06 per basic and diluted share

Catalyst Pharmaceutical Partners first-quarter net loss decreases to $0.06 per basic and diluted share

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Simcere Pharmaceutical first-quarter total revenue up 3.7% to $67.2 million

Simcere Pharmaceutical first-quarter total revenue up 3.7% to $67.2 million

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

ICU-acquired infection rates are not indication of patients' mortality risk: Researchers

ICU-acquired infection rates are not indication of patients' mortality risk: Researchers

Thai AIDS vaccine trial: Risk of HIV infection can be reduced with a vaccine

Thai AIDS vaccine trial: Risk of HIV infection can be reduced with a vaccine

Final data from Open-Label studies of Cinryze in patients with HAE now available

Final data from Open-Label studies of Cinryze in patients with HAE now available

Phase II ALSTAR trial: Talampanel is safe for ALS patients

Phase II ALSTAR trial: Talampanel is safe for ALS patients

Apnex HGNS System shows promising results in people suffering from OSA

Apnex HGNS System shows promising results in people suffering from OSA

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR

Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.